ArticleCancer discovery2022
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
Pasi A Jänne et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
195 papers cite itlatest 60 shown
this paperpooled ittrialcites it